Cargando…
Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era
Acquired drug resistance (ADR) is common among adolescents living with perinatal HIV (APHI) in sub-Saharan Africa (SSA). Personalized management has the potential to improve pediatric antiretroviral therapy (ART), even in the presence of long-term treatment and HIV-1 subtype diversity. We sought to...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658463/ https://www.ncbi.nlm.nih.gov/pubmed/38020274 http://dx.doi.org/10.4081/jphia.2023.2612 |
_version_ | 1785137422707720192 |
---|---|
author | PABO, WILLY LE ROI TOGNA NJUME, DEBIMEH NDIP, ROLAND NDIP TAKOU, DÉSIRÉ SANTORO, MARIA-MERCEDES CHENWI, COLLINS BELOUMOU, GRACE SEMENGUE, EZECHIEL NGOUFACK JAGNI NKA, ALEX DURAND KA'E, AUDE CHRISTELLE TETO, GEORGES DAMBAYA, BEATRICE DJUPSA, SANDRINE NYASA, RAYMOND BABILA ANGUECHIA, DAVY HYACINTHE GOUISSI KAMTA, CEDRIC BALA, LIONEL LAMBO, VIRGINIE SOSSO, SAMUEL MARTIN COLIZZI, VITTORIO PERNO, CARLO FEDERICO FOKAM, JOSEPH NDJOLO, ALEXIS |
author_facet | PABO, WILLY LE ROI TOGNA NJUME, DEBIMEH NDIP, ROLAND NDIP TAKOU, DÉSIRÉ SANTORO, MARIA-MERCEDES CHENWI, COLLINS BELOUMOU, GRACE SEMENGUE, EZECHIEL NGOUFACK JAGNI NKA, ALEX DURAND KA'E, AUDE CHRISTELLE TETO, GEORGES DAMBAYA, BEATRICE DJUPSA, SANDRINE NYASA, RAYMOND BABILA ANGUECHIA, DAVY HYACINTHE GOUISSI KAMTA, CEDRIC BALA, LIONEL LAMBO, VIRGINIE SOSSO, SAMUEL MARTIN COLIZZI, VITTORIO PERNO, CARLO FEDERICO FOKAM, JOSEPH NDJOLO, ALEXIS |
author_sort | PABO, WILLY LE ROI TOGNA |
collection | PubMed |
description | Acquired drug resistance (ADR) is common among adolescents living with perinatal HIV (APHI) in sub-Saharan Africa (SSA). Personalized management has the potential to improve pediatric antiretroviral therapy (ART), even in the presence of long-term treatment and HIV-1 subtype diversity. We sought to evaluate the effect of HIV-1 mutational profiling on immuno-virological response and ADR among APHI. A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon. Clinical, immunological and virological responses were measured at enrolment (T1), 6-months (T2) and 12-months (T3). Immunological failure (IF: CD4 #x003C;250 cells/mm(3)), VF (viremia ≥1,000 copies/ml), and ADR were analyzed, with P#x003C;0.05 considered significant. Mean age was 15(±3) years; male-female ratio was 1:1; median [IQR] ART-duration was 36[21-81] months. At T1, T2, and T3 respectively, adherence-level was 66.4, 58.3 and 66.5%; 14 viral clades were found, driven by CRF02_AG (58.6%); ADR-mutations favored increased switch to second-line ART (16.1, 31.2, and 41.9%, P#x003C;0.0001). From T1-T3 respectively, there were declining rates of IF (25.5, 18.9, and 9.83%, P#x003C;0.0001), VF (39.7, 39.9, and 28.2%, P=0.007), and HIVDR (96.4, 91.7, and 85.0%, P=0.099). Predictors of ADR were being on first-line ART (P=0.045), high viremia at enrolment (AOR=12.56, P=0.059), and IF (AOR=5.86, P=0.010). Of note, optimized ART guided by mutational profile (AOR=0.05, P=0.002) was protective. Moreover, full Tenofovir+Lamivudine+Dolutegravir efficacy was predicted in 77 and 62% of APHI respectively after first- and second-line failure. Among APHI in this SSA setting, viral mutational profiling prompts the use of optimized Dolutegravir-based ART regimens, leading to improved immuno-virological response and declining ADR burdens. Thus, implementing personalized HIV medicine in this vulnerable population would substantially improve ART response and the achievement of the 95-95-95 goals in these underserved populations. |
format | Online Article Text |
id | pubmed-10658463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | PAGEPress Publications, Pavia, Italy |
record_format | MEDLINE/PubMed |
spelling | pubmed-106584632023-10-01 Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era PABO, WILLY LE ROI TOGNA NJUME, DEBIMEH NDIP, ROLAND NDIP TAKOU, DÉSIRÉ SANTORO, MARIA-MERCEDES CHENWI, COLLINS BELOUMOU, GRACE SEMENGUE, EZECHIEL NGOUFACK JAGNI NKA, ALEX DURAND KA'E, AUDE CHRISTELLE TETO, GEORGES DAMBAYA, BEATRICE DJUPSA, SANDRINE NYASA, RAYMOND BABILA ANGUECHIA, DAVY HYACINTHE GOUISSI KAMTA, CEDRIC BALA, LIONEL LAMBO, VIRGINIE SOSSO, SAMUEL MARTIN COLIZZI, VITTORIO PERNO, CARLO FEDERICO FOKAM, JOSEPH NDJOLO, ALEXIS J Public Health Afr Original Article Acquired drug resistance (ADR) is common among adolescents living with perinatal HIV (APHI) in sub-Saharan Africa (SSA). Personalized management has the potential to improve pediatric antiretroviral therapy (ART), even in the presence of long-term treatment and HIV-1 subtype diversity. We sought to evaluate the effect of HIV-1 mutational profiling on immuno-virological response and ADR among APHI. A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon. Clinical, immunological and virological responses were measured at enrolment (T1), 6-months (T2) and 12-months (T3). Immunological failure (IF: CD4 #x003C;250 cells/mm(3)), VF (viremia ≥1,000 copies/ml), and ADR were analyzed, with P#x003C;0.05 considered significant. Mean age was 15(±3) years; male-female ratio was 1:1; median [IQR] ART-duration was 36[21-81] months. At T1, T2, and T3 respectively, adherence-level was 66.4, 58.3 and 66.5%; 14 viral clades were found, driven by CRF02_AG (58.6%); ADR-mutations favored increased switch to second-line ART (16.1, 31.2, and 41.9%, P#x003C;0.0001). From T1-T3 respectively, there were declining rates of IF (25.5, 18.9, and 9.83%, P#x003C;0.0001), VF (39.7, 39.9, and 28.2%, P=0.007), and HIVDR (96.4, 91.7, and 85.0%, P=0.099). Predictors of ADR were being on first-line ART (P=0.045), high viremia at enrolment (AOR=12.56, P=0.059), and IF (AOR=5.86, P=0.010). Of note, optimized ART guided by mutational profile (AOR=0.05, P=0.002) was protective. Moreover, full Tenofovir+Lamivudine+Dolutegravir efficacy was predicted in 77 and 62% of APHI respectively after first- and second-line failure. Among APHI in this SSA setting, viral mutational profiling prompts the use of optimized Dolutegravir-based ART regimens, leading to improved immuno-virological response and declining ADR burdens. Thus, implementing personalized HIV medicine in this vulnerable population would substantially improve ART response and the achievement of the 95-95-95 goals in these underserved populations. PAGEPress Publications, Pavia, Italy 2023-10-01 /pmc/articles/PMC10658463/ /pubmed/38020274 http://dx.doi.org/10.4081/jphia.2023.2612 Text en Copyright © 2023, the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0). |
spellingShingle | Original Article PABO, WILLY LE ROI TOGNA NJUME, DEBIMEH NDIP, ROLAND NDIP TAKOU, DÉSIRÉ SANTORO, MARIA-MERCEDES CHENWI, COLLINS BELOUMOU, GRACE SEMENGUE, EZECHIEL NGOUFACK JAGNI NKA, ALEX DURAND KA'E, AUDE CHRISTELLE TETO, GEORGES DAMBAYA, BEATRICE DJUPSA, SANDRINE NYASA, RAYMOND BABILA ANGUECHIA, DAVY HYACINTHE GOUISSI KAMTA, CEDRIC BALA, LIONEL LAMBO, VIRGINIE SOSSO, SAMUEL MARTIN COLIZZI, VITTORIO PERNO, CARLO FEDERICO FOKAM, JOSEPH NDJOLO, ALEXIS Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era |
title | Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era |
title_full | Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era |
title_fullStr | Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era |
title_full_unstemmed | Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era |
title_short | Genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in Cameroon: Implications in the dolutegravir-era |
title_sort | genotypic resistance testing improves antiretroviral treatment outcomes in a cohort of adolescents in cameroon: implications in the dolutegravir-era |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658463/ https://www.ncbi.nlm.nih.gov/pubmed/38020274 http://dx.doi.org/10.4081/jphia.2023.2612 |
work_keys_str_mv | AT pabowillyleroitogna genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT njumedebimeh genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT ndiprolandndip genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT takoudesire genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT santoromariamercedes genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT chenwicollins genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT beloumougrace genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT semengueezechielngoufackjagni genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT nkaalexdurand genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT kaeaudechristelle genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT tetogeorges genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT dambayabeatrice genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT djupsasandrine genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT nyasaraymondbabila genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT anguechiadavyhyacinthegouissi genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT kamtacedric genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT balalionel genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT lambovirginie genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT sossosamuelmartin genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT colizzivittorio genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT pernocarlofederico genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT fokamjoseph genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera AT ndjoloalexis genotypicresistancetestingimprovesantiretroviraltreatmentoutcomesinacohortofadolescentsincameroonimplicationsinthedolutegravirera |